Study finds drug warning labels need overhaul

Many patients seem to ignore prescription drug warning labels with instructions that are critical for safe and effective use, according to a study by a Kansas State University researcher working with scientists at Michigan State University.

Consumers, particularly older ones, often overlook prescription drug warning labels in part because the labels fail to attract attention, said Nora Bello, an assistant professor of statistics at Kansas State University. Bello helped investigate the effectiveness of prescription drug warning labels to convey drug information to patients. She and experts in packaging and psychology found that prescription drug warning labels fail to capture patients' attention, impairing the communication of important safety information. The research is published in PLoS ONE.

"These findings have implications for the design of prescription drug warning labels to improve their effectiveness, particularly as the U.S. government recently started to investigate approaches to standardize the format and content of these labels to decrease medication error rates," Bello said. "Results from this study can provide insight to assist debates about labeling designs that are most likely to impact a wide age range of consumers."

About 15 million medication errors occur each year in the United States, and most happen at home where patients are responsible for complying with medication regimes. Prescription warning labels are intended to serve as quick reminders of the most important instructions for safe and effective drug use to prevent injuries from medications. They can include, for example, warnings against accompanying use of the medication with alcohol or driving.

The findings show that older patients do not always pay attention to drug warning labels. The results are worrisome, Bello said, because this population is reportedly at a greater risk for dangerous medication errors given their usually more complicated drug regimes relative to younger patients.

Researchers tracked study participants' eye movements over labels on a prescription drug vial to measure attention. The participants interacted with vials under a hypothetical scenario of just having been delivered prescription medications from the pharmacy.

In the study, the eye gaze of 50 percent of participants older than 50 years of age failed to notice a warning label on prescription vials. For 22 percent of these participants, their vision did not enter the warning label area in any of the five vials they interacted with. In contrast, 90 percent of young adults between ages 20 and 29 fixated on the warning labels.

This difference was partially attributed to the age-specific dynamic of visual fixation of information between the age groups, researchers said.

The data provided a compelling case that understanding consumers' attentive behavior and how to attract their attention is crucial to developing an effective labeling standard for prescription drugs, researchers said.

Collaborators include Michigan State University researchers Mark Becker and Laura Bix and Michigan State University graduate student Raghav Sundar. Research was partially funded through the Center for Food and Pharmaceutical Packaging Research at Michigan State University.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...